Adamis acquires prostrate drug candidates from Colby Pharmaceuticals Adamis Pharmaceuticals Company.

Carlo, President and CEO of Adamis stated The next few months should be an exciting time for Adamis; a few of the near term milestones includes submitting the IND for APC-100 Stage I/IIa prostate tumor clinical trial, submitting an IND for a Phase II telomerase cancers vaccine clinical trial, start making of our second prostate medication APC-200 and publication and announcement of the Phase III efficacy results of our C31G contraception product.. Adamis acquires prostrate drug candidates from Colby Pharmaceuticals Adamis Pharmaceuticals Company , today announced the completion of the acquisition from Colby Pharmaceuticals of the rest of the exclusive license agreements associated with two drug product candidates for the treating prostate tumor .To help expand confirm these results and to exclude the chance of cross-contamination between your cultures for the individual and Camel B, RNA samples that were extracted from the initial nasal swabs attained from the individual and from Camel B were subjected to partial genome sequencing of 242-bp fragments and 312-bp fragments in the RdRp and N parts of the viral genome, respectively. Alignment of the two fragments from the two samples confirmed that these were identical. Full genome sequencing of lifestyle isolates obtained from the individual and from Camel B showed that both samples were 100 percent identical.